BioBrief covers a catalyst-driven biotech session, with late-stage clinical data rewarded while regulatory scrutiny weighed on weaker oncology evidence packages.

In today’s BioBrief:

• Cytokinetics / aficamten — Positive Phase 3 data in non-obstructive hypertrophic cardiomyopathy showed statistically significant improvements in symptoms and exercise capacity, expanding the potential HCM franchise beyond obstructive disease.
• Viridian / elegrobart — Phase 3 data in chronic thyroid eye disease showed proptosis responder rates of about 50 percent and 54 percent versus 15 percent for placebo, supporting Viridian’s subcutaneous TED strategy.
• Replimune / RP1 — The FDA publicly defended its rejection of Replimune’s oncology therapy, reinforcing concern around single-arm evi ...